Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study-Reference-Cited by-同舟云学术

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study

Published:1995-01 Issue:6 Volume:49 Page:269-277
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Goto Y,Hotta N,Shigeta Y,Sakamoto N,Kikkawa R

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference22 articles.

1. The sorbitol pathway and the complications of diabetes;Gabbay;N Engl J Med,1973

2. Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy;Greene;Diabetes Care,1985

3. Altered myoinositol metabolism in diabetic nerve;Greene,1987

4. Aldose reductase inhibitors;Hotta,1990

5. Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissues;Ward;Diabetes,1972

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel drugs affecting diabetic peripheral neuropathy;IRAN J BASIC MED SCI;2024

2. Aldo-keto reductase 1B: Much learned, much more to do;hLife;2023-12

3. N-Acetylcysteine overcomes epalrestat-mediated increase of toxic 4-hydroxy-2-nonenal and potentiates the anti-arthritic effect of epalrestat in AIA model;International Journal of Biological Sciences;2023

4. Diabetic Neuropathy and Rehabilitation Treatment;The Japanese Journal of Rehabilitation Medicine;2022-12-18

5. New horizons of biomaterials in treatment of nerve damage in diabetes mellitus: A translational prospective review;Frontiers in Endocrinology;2022-10-27